关键信息
-
基因名
botA
- 应用
-
别名
botA；KIAA1054；Synaptic vesicle glycoProtein 2C
-
种属
E.coli
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P0DPI0
-
表达区间
1-436aa
-
氨基酸序列
MPFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVRGIIT
-
分子量
52.0 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
Botulinum toxin, produced by the bacteria *Clostridium botulinum*, is one of the most potent neurotoxins known, primarily affecting the nervous system and leading to Botulism, a serious illness characterized by muscle paralysis. The toxin comprises several serotypes, with botA being a subtype of particular interest due to its unique properties and potential applications in both medical and cosmetic fields. Research has shown that recombinant botA proteins can be synthesized using modern biotechnological methods, allowing for the exploration of their structure-function relationships and mechanisms of action. The ability to produce botA in a laboratory setting offers significant advantages over traditional extraction methods, which can be hazardous and inefficient. Furthermore, understanding the molecular details of botA and its interaction with neuromuscular junctions is critical not only for therapeutic developments, such as targeted treatments for spasticity and chronic pain but also for designing safer forms of the toxin for cosmetic procedures. Ongoing studies are focused on characterizing recombinant botA's pharmacological profiles, optimizing production techniques, and assessing its safety and efficacy in preclinical models. This research is pivotal for advancing our knowledge of botulinum neurotoxins and expanding their applications, ultimately benefiting both therapeutic and cosmetic domains.
